Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Private Capital Markets

<ul>
 <li>
Pioneering Host-Response Diagnostics: <a href="https://smartkarma.com/entities/memed">MeMed</a> is a leader in the advanced field of host-response diagnostics, developing and commercializing technology that decodes the body's immune system to distinguish between bacterial and viral infections. Its flagship product, the <a href="https://smartkarma.com/entities/memed">MeMed</a> BV test run on the <a href="https://smartkarma.com/entities/memed">MeMed</a> Key platform, provides actionable results in 15 minutes, addressing the major clinical dilemma of antibiotic misuse and the growing threat of antimicrobial resistance (AMR).</li>
 <li>
Significant Market Opportunity &amp; Regulatory Validation: The company targets the large and growing point-of-care diagnostics market, with a focus on infectious diseases. <a href="https://smartkarma.com/entities/memed">MeMed</a> has achieved significant regulatory milestones, including 510(k) clearance from the U.S. FDA for <a href="https://smartkarma.com/entities/memed">MeMed</a> BV for both adults and children, a CE Mark in Europe, and approval from Health Canada, validating its technology and paving the way for commercial adoption.</li>
 <li>
Strong Financial Backing and Strategic Partnerships: <a href="https://smartkarma.com/entities/memed">MeMed</a> is a private, venture-backed company that has raised over $200 million from a diverse group of investors. The company is scaling up manufacturing and commercialization, particularly in the U.S., supported by strategic partnerships with organizations like the U.S. Department of Defense and collaborations with diagnostic companies to run its tests on high-throughput analyzers.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Pioneering Host-Response Diagnostics: MeMed is a leader in the advanced field of host-response diagnostics, developing and commercializing technology that decodes the body's immune system to distinguish between bacterial and viral infections. Its flagship product, the MeMed BV test run on the MeMed Key platform, provides actionable results in 15 minutes, addressing the major clinical dilemma of antibiotic misuse and the growing threat of antimicrobial resistance (AMR).
  
Significant Market Opportunity &amp; Regulatory Validation: The company targets the large and growing point-of-care diagnostics market, with a focus on infectious diseases. MeMed has achieved significant regulatory milestones, including 510(k) clearance from the U.S. FDA for MeMed BV for both adults and children, a CE Mark in Europe, and approval from Health Canada, validating its technology and paving the way for commercial adoption.
  
Strong Financial Backing and Strategic Partnerships: MeMed is a private, venture-backed company that has raised over $200 million from a diverse group of investors. The company is scaling up manufacturing and commercialization, particularly in the U.S., supported by strategic partnerships with organizations like the U.S. Department of Defense and collaborations with diagnostic companies to run its tests on high-throughput analyzers.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Israel

The company develops immuno-personalized diagnostic devices for the detection of bacterial and viral infections. Its technology distinguishes between infection types by analyzing patient immune responses, providing clinicians with rapid data to inform antibiotic treatment decisions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MeMed (MEMED IT)

Primer: MeMed (MEMED IT) - May 2026

Pioneering Host-Response Diagnostics: MeMed is a leader in the advanced field of host-response diagnostics, developing and commercializing...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)